InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) Registry
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00273182|
Recruitment Status : Completed
First Posted : January 9, 2006
Results First Posted : August 5, 2013
Last Update Posted : August 5, 2013
Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes.
When there are changes in the heart beat sometimes an implantable heart device is used to control the rate and rhythm of the heart beat. In certain heart failure cases, when the two lower chambers of the heart no longer beat in a coordinated manner, cardiac resynchronization therapy (CRT) may be prescribed. CRT is similar to a pacemaker. It is placed (implanted) under the skin of the upper chest. CRT is delivered as tiny electrical pulses to the right and left ventricles through three or four leads (soft insulated wires) that are inserted through the veins to the heart.
The purpose of this study is to monitor the long-term performance of the InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) systems for cardiac resynchronization therapy (CRT).
|Condition or disease||Intervention/treatment|
|Heart Failure Cardiomyopathy||Device: InSync Model 8040 Device: InSync III Model 8042|
|Study Type :||Observational|
|Actual Enrollment :||1999 participants|
|Official Title:||InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) Systems for Cardiac Resynchronization Therapy (CRT) - InSync Registry|
|Study Start Date :||March 2002|
|Actual Primary Completion Date :||April 2011|
|Actual Study Completion Date :||April 2011|
Patients implanted with InSync Model 8040, InSync III Model 8042 , or Medtronic CRT-D system. A total of 1999 subjects were enrolled in the study. Of them, 1738 had successful post market implants of InSync Model 8040 (601 subjects), InSync III Model 8042 (512 subjects) and CRT-D devices (625 subjects). The rest 262 subjects came from two pre-market studies: the MIRACLE study added 141 subjects to InSync Model 8040, and the InSync III study added 121 subjects to the InSync III Model 8042. A total of 1014 subjects completed the study through 36 month follow up. Follow-up of 1000 subjects was required by the FDA to satisfy the conditions of approval.
Device: InSync Model 8040
Subjects with sucessful implants of InSync Model 8040.Device: InSync III Model 8042
Subjects with successful implants of InSync III Model 8042
- Overall Death Rate and Cause Specific Death Rate During Three Years Post Implant. [ Time Frame: 36 month follow-up ]Survival curves of overall mortality and cause specific mortality (due to progressive heart failure and sudden cardiac death) were created based on Kaplan-Meier estimates. Estimates went out to 36 month time point. Confidence intervals were calculated on a log-log scale. The Kaplan-Meier estimates are reported in the statistical analysis modules
- Left Ventricular (LV) Lead R-wave Amplitude [ Time Frame: 36 month follow-up ]Summary statistics such as mean and 95% CI for the LV lead R-wave amplitude during the 36 months of follow-up.
- Left Ventricular (LV) Lead Impedance [ Time Frame: 36 months follow-up ]Summary statistics such as mean and 95% CI for the LV lead impedance during the 36 months of follow-up.
- Left Ventricular (LV) Lead Pacing Voltage Threshold [ Time Frame: 36 months follow-up ]Summary statistics such as mean and 95% CI for the LV lead pacing voltage threshold during the 36 months of follow-up
- Subjects With Left Ventricular (LV) Lead Related Complications During Three Years Post-implant [ Time Frame: 36 months follow-up ]
A left ventricular lead related complication is defined as an adverse event that requires invasive intervention or leads to loss of significant device function resulting from the presence or performance of the LV lead.
Kaplan-Meier method was used to estimate complication-free rate during the three years of follow-up. Time to the first post-implant LV lead related complication was used for the calculation. Confidence intervals were calculated on a log-log scale.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273182
Show 82 Study Locations
|Study Chair:||InSync Registry Study Leader||Medtronic|